Sunesis Pharmaceuticals, Inc.
Sunesis begins clinical study of anticancer drug
Published in Healthcare Mergers, Acquisitions and Ventures Week, July 31st, 2004
The trial is an open-label multi-center, dose escalation study designed to examine the safety, tolerability, and pharmacokinetics of SNS-595 in order to establish optimal dosing regimens for use in Phase II clinical testing. The drug is a first-in-class cell cycle modulator that kills proliferating cancer cells by inducing apoptosis, or programmed cell death.
Patients with advanced malignancies are being enrolled at four centers in the U.S. In the first trial, SNS-595 will be administered as a single...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
More Articles from Healthcare Mergers, Acquisitions and Ventures Week
- ACI Medical Inc.
New Medicare-approved device prevents amputations through increased circulation - ATS Medical, Inc.
Medical device company closes on sale of $13.1M of common stock - Acambis plc
David Lawrence named CFO at pharmaceutical firm - Acorda Therapeutics
Jane Wasman hired as executive VP, general counsel at pharmaceutical firm - Agenix, Ltd.
AGEN settles Synbiotics litigation - Albemarle Corp.
Dividend declared by specialty chemicals company - More from this issue of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
